1. Pink Sheet
  2. >>Market Access

PhRMA’s Opening Gambit: Limiting Medicare Price Setting To The IRA's Minimum Discount

 
• By Cathy Kelly

CMS should adopt the minimum price reductions under the Inflation Reduction Act for most selected drugs in the early years of the Medicare price negotiation program, PhRMA urges and recommends the agency should retain that approach in the long-term for younger drugs, those targeting an unmet medical need or those representing therapeutic advances.

chess
• Source: Shutterstock

The Centers for Medicare and Medicaid Services does not have the expertise or time to create the complex program for setting drug prices in Medicare envisioned by the Inflation Reduction Act and so should default to setting prices at the minimum discount level established by the law for drugs less than 13 years old for “several years,” the Pharmaceutical Research and Manufacturers of America argues in comments to the agency.

The voluminous comments, submitted on 14 April, represent one of the few opportunities industry has to weigh in on the Medicare price negotiation program and try to shape it

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

More from Pink Sheet

Novavax’s COVID-19 Vaccine Label Narrowed After Political Officials Intervened

 
• By Sarah Karlin-Smith

The label that Novavax's COVID-19 vaccine was slated to receive before political officials held up the approval was broader than was granted 16 May.

Biomarker Negativity At Issue In Pfizer Bid To Broaden Talzenna CRPC Claim

 
• By Bridget Silverman

The FDA questioned Pfizer’s reliance on a “large, incompletely defined” subgroup of castration-resistant prostate cancer patients without known HRR gene alterations in its review of the proposed expansion of Talzenna’s first-line indication for HRR-mutated CRPC to an all-comers population.

UroGen’s Mitomycin: Are Randomized Trials For Bladder Cancer Necessary?

 
• By Sue Sutter

The Oncologic Drugs Advisory Committee will vote on the risk-benefit of UGN-102 for low-grade, intermediate-risk, non-muscle invasive bladder cancer based on data from a single-arm trial, but the FDA also seeks input on requiring randomized studies for future treatments.